Andere Sprachen GRI BIOPAR

Aktien

A3D4D0

US3622AW1069

GRI

Verzögert Nasdaq Andere Börsenplätze 18:52:01 03.07.2024			% 5 Tage	% 1. Jan.
1.6 ^USD	-2.44%		-12.57%	-76.12%

26.06.	Wall Street eröffnet vor neuen Hausverkäufen und BIP-Zahlen geringfügig niedriger	MT
26.06.	Die größten Verlierer der Vorbörse	MT

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine	02.07.
GRI Bio to Present at the 8th Annual IPF Summit	01.07.
GRI Bio Announces Closing of $4.0 Million Public Offering	28.06.
GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators	27.06.
GRI Bio Announces Pricing of $4 Million Public Offering	27.06.
Wall Street Set to Open Marginally Lower Ahead of New Home Sales, GDP Figures	26.06.
Top Premarket Decliners	26.06.
Investors Await New Home Sales, GDP Data as US Futures Mixed in Wednesday's Premarket	26.06.
GRI Bio Files Shelf for Common Stock Sale	20.06.
GRI Bio Announces Reverse Stock Split	14.06.
GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor Pitch Conference	11.06.
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs	22.05.
GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)	21.05.
GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)	20.05.
GRI Bio to Present at Alliance Global Partner’s 2024 Healthcare Company Showcase	14.05.
GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update	13.05.
GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity	29.04.
GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar	25.04.
GRI Bio Receives South Korea Patent for Liver Inflammatory Condition Treatments	16.04.
GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent	16.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen GRI BIOPAR

Aktien

A3D4D0

US3622AW1069

GRI

Andere Sprachen

Filter